Amprologix Limited

Based in the UK, Amprologix Limited specializes in developing innovative antibiotics aimed at addressing the urgent challenge of antibiotic resistance. Amprologix Limited, founded in 2018 and headquartered in Plymouth, UK, operates in the pharmaceutical sector focusing on novel antibiotic development. The company has secured GBP 740,000 in pre-Series A funding from Plutus Investment Group on October 20, 2025, which constitutes its total amount raised. The firm has completed one deal to date.

Amprologix specializes in the development of innovative antibiotics to combat the escalating threat of antibiotic resistance. Their core product, NI01, is a potent bactericidal peptide designed for topical application against bacteria identified by the World Health Organization as priority pathogens. NI01 demonstrates significant efficacy in preclinical models, particularly against methicillin-resistant Staphylococcus aureus (MRSA), outperforming the current standard treatment, mupirocin. The company has also created a family of novel therapeutics, known as the ‘NI01-family,’ which exhibit narrow-spectrum antibacterial activity with minimal risk of developing resistance.

Amprologix primarily targets healthcare providers and institutions within the pharmaceutical sector, focusing on markets across North America, Europe, and Asia, where the demand for effective antibiotic solutions is critical. Amprologix operates on a transactional model focused on partnerships and collaborations within the pharmaceutical industry. The company engages with healthcare providers, hospitals, and pharmaceutical distributors, facilitating the delivery of its antibiotic products directly to medical professionals who require effective treatment solutions for resistant bacterial infections. The revenue stream is derived from sales of NI01 and its derivative products, with transactions structured around product distribution agreements and research collaborations.

Each transaction is designed to ensure that Amprologix's advanced therapeutics reach the end-users—healthcare practitioners and their patients—ensuring access to groundbreaking treatments in the fight against antimicrobial resistance. The company’s innovative approach positions it well within an evolving market that prioritizes new antibiotic therapies. In October 2025, Amprologix Limited raised GBP 740,000 in pre-Series A funding from Plutus Investment Group to support the development of its novel antibiotics. The company plans to utilize these funds for enhancing existing products and launching upcoming new treatments targeting resistant bacterial strains.

Additionally, Amprologix is focused on expanding into North America, Europe, and Asia, where the demand for innovative antibiotic solutions is high.